A knowledge of pharmacokinetic principles is essential to understand dosage modification for drugs used in patients in renal failure. Dosage modification is indicated either where drugs have a low therapeutic index, or where renal mechanisms play a major role in drug elimination. Drug renal clearance can be indexed to creatinine clearance in order to gauge the degree of drug elimination impairment. Two schemes of dosage modification have been proposed; dosage interval extension or dosage size reduction. In addition to effects on drug elimination, renalfailure may also alter drug absorption, distribution, protein binding and metabolism. Dialysis regimens, by eliminating drugs to a greater or lesser degree, have implications for drug therapy.
The elimination of drugs excreted partly or entirely by the kidneys is slower than normal in patients with renal disease. As a consequence, when such a drug is administered repeatedly over a prolonged period of time, drug accumulation and the concomitant risk of toxic side effects will be more pronounced in these patients unless the drug regimen is adapted to the functional renal state of the individual patient. The practical importance of the problem may be illustrated by the fact that the elimination rate of some rather toxic drugs, such as the aminoglycosides, may be up to fifty times slower than normal in severely uraemic patients. There is no other known factor influencing drug elimination to such an extreme degree. i Theoretically, the problem could be overcome by measuring the plasma concentrations of drugs in all patients with renal impairment. The assumption would be that renal disease in no way altered the response of the patient to that drug. This approach is not feasible logistically, since even in highly specialised units the drug assay service is limited in scope. By a knowledge of basic pharmacokinetic principles combined with pharmacokinetic properties of the drug in question, it is possible to design a therapeutic regimen with a much higher degree of safety and efficacy than is possible by empirical means only. Quantitative information about the functional renal impairment of the patient is essential. As a goal, the active concentrations of drugs resulting in patients with renal disease should be the same, and should follow the same time course as in patients with normal renal function. Drug accumulation is a process which can be completely regulated by the therapist provided that the modified pharmacokinetic parameters are understood. Although the elimination rate is peculiar to the individual drug in a particular patient, the extent of drug accumulation is not a characteristic of the drug itself, but rather is a property of the dosage regimen.
The aims of this paper are to discuss the influence of renal failure on drug absorption, distribution, metabolism and elimination and to describe various methods currently used to obtain satisfactory drug concentrations in the uraemic patient. Because most clinical importance concerns the effects of renal impairment on drug elimination, most emphasis will be placed on this area, and examples will be given for drugs commonly encountered in the practice of anaesthesia and intensive care.
PHARMACOKINETIC TERMS
Since manipulation of drug dosage regimens requires a good grasp of pharmacokinetic principles, the following brief summary is presented. The half-life of a drug (TYz) is the time taken for the concentration in the blood to fall to half of a previous value. This may be a single value or one of several values depending on the distributional characteristics of the drug in the body. The volume of distribution of a drug (V d) is equal to the ratio of the amount of drug in the body to its concentration in the plasma (or blood). There may be more than one volume of distribution depending on the rate of distribution within the body and therefore on such characteristics of the drug as lipid and water solubility and degree of binding to plasma and tissue proteins. It also depends on characteristics of the patient such as size, body composition and plasma protein concentrations, but the relationships are not always based on linear functions. The concept of volume of distribution is primarily a mathematical one used to relate the dose of a drug to the plasma concentration achieved by that dose but may, for certain substances, have anatomical or physiological significance. For example, for certain drugs such as radioiodinated serum albumen, the mathematical volume of distribution determined shortly after intravenous injection is equal to the anatomical plasma volume, and thus this drug can be used to measure plasma volume. For most drugs, however, the volume of distribution does not represent a discrete anatomical compartment, but rather equates a fictitious homogeneous volume to the actual heterogeneous distribution of the drug throughout the body. Another important function of the volume of distribution is as a proportionality factor relating the clearance of the drug to its half-life. The clearance of a drug is a measure of the functional ability of the body to remove it independently of other pharmacokinetic processes. It is often defined as the volume of plasma from which the drug is, in effect, completely removed per unit time by the body's eliminating mechanisms. Obviously this is a virtual volume, not a real volume. No single millilitre of plasma necessarily has all its drug removed in one transit through eliminating organs. Rather, a fraction is removed from each millilitre perfusing the organ. This amount is summed and expressed as though it were derived by completely clearing a smaller volume of plasma of all its contained drug. In terms of renal elimination, renal clearance may be defined in terms of the loss of drug across the kidney as the product of the plasma flow (Qr) and the renal extraction ratio (Er) (Equation 1).
CL r = Qr.Er ... (1) (where Er = concentration of drug in renal arterial plasma -concentration of drug in renal venous plasma/concentration of drug in renal arterial plasma). Clearance, therefore, has units of flow. Strictly, clearance is given by the product of extraction ratio, based on whole blood concentrations, and blood flow. A discrepancy occurs for substances which are partitioned into blood cells differently in arterial and venous blood. The traditional definitions arose because the majority of test substances used in the measurement of flow tended to be restricted to the plasma (e.g. BSP, hippuran, inulin) so that this consideration did not apply. For techniques of measurement of drug clearance by the kidney, the review of Tucker z should be consulted. If renal excretion contributes significantly to the overall elimination of a drug, i.e. renal clearance is about 50070 or more of total clearance, changes in renal clearance may have profound implications for the duration of pharmacological or toxic effects. It is especially important to have reliable information about the renal clearance of drugs and their metabolites in patients with impaired kidney function. In addition, a knowledge of whether the renal clearance of a drug can be made to become the major component of total clearance may help in the management of overdosage.
EFFECTS OF RENAL FAILURE ON DRUG KINETICS

Absorption
There is little quantitative information available on the influence of impaired renal function on oral or intramuscular absorption.
Most studies have concentrated on antibiotics and have suggested that with trimethoprim, 3 cloxacillin 4 and cefazolin 5 there is no impairment of absorption mechanisms in uraemia. However, hepatic drug metabolism may be impaired in the uraemic patient and this may result in changes in the bioavailability of drugs which are extensively metabolised during their first pass through the liver after oral doses. 6 ,7 There is evidence that the duration of brachial plexus blockade is shortened in patients with renal failures and this provides indirect evidence that systemic absorption of local anaesthetic is faster than in normal patients. Whether this is a reflection of circulatory hyperkinesis due to decreased viscosity (and, therefore, is a generalised phenomenon of perfusion-limited absorption processes) remains to be investigated further.
Drug distribution
As will be seen later, most dose adjustment methods for renal impairment assume that the volume of distribution of a drug is essentially unaltered in patients with compromised renal function. Gibaldi and Perrier 9 ,!O were the first to examine this assumption more closely. It was shown that a redistribution of drug in the body may occur in renal impairment, resulting in concentration of drug in a central compartment at the expense of that in a tissue compartment. The distribution volume of digoxin has been reported to be reduced from an average of 510 litres in normal subjects to be between 230 and 380 litres in patients with renal disease. 7 ,1I It was postulated that the reduced apparent volume may be due to a decrease in extracellular fluid volume or a decrease in binding of digoxin to tissue. Increased apparent distribution volumes in renal failure have been associated with deceased binding to plasma proteins of several drugs, primarily organic acids. 12 -14 The causative factor of reduced binding has not been identified. The reduction is greater than can be accounted for by hypoalbuminaemia and is not corrected by haemodialysis. 7 ,15,16
Protein binding
Numerous studies have been performed which show that the free concentration of drug in plasma correlates more closely with the concentration of drug at receptor sites, and therefore with observed pharmacologic effect, than does the total concentration of drug in plasma.
Therefore, any reduction in the plasma protein binding of a drug in an individual patient will increase free drug concentrations leading to increased drug effect and possible toxicity. Such protein binding changes have been found in renal failure. As stated in a recent review, 17 the protein binding of the few basic drugs studied has generally been normal or decreased. Acidic drugs are largely bound to albumen in plasma and the decrease in binding in uraemic plasma has been attributed to qualitative changes in the binding sites, to endogenous inhibitors of binding, and to decreased concentrations of albumen. 1s -22 Protein binding of diazepam is reduced in uraemia,z3 all the above mechanisms being implicated. The nature of the plasma protein binding of lignocaine has only recently been described in normal man 24 ,25 and in patients with renal disease. 23 The principal binding protein for lignocaine is a)-acid glycoprotein (AAG), an acute phase reactant whose concentration is increased in a wide variety of conditions such as myocardial infarction, malignancy, renal transplantation, surgery, ulcerative colitis and Crohn's disease. 17 The binding of lignocaine was increased in uraemic patients, as it was in renal transplant patients. 23 This elevation was associated with a marked elevation of the AAG concentration. However, patients with nephrotic syndrome had no change in lignocaine binding or AAG level. Other drugs that have been shown to bind to AAG include dipyridamole, quinidine, alprenolol, impramine, propranolol, etidocaine, bupivacaine, methadone and disopyramide. 17 However, quinidine is the only other drug shown to have increased binding in disease states. 26 Of particular clinical interest are the protein binding changes of thiopentone associated with chronic renal failure. Protein binding of thiopentone has been shown to be reduced from 880/0 in normal patients to 47% in patients with chronic renal failure. 27 The resulting increase in free drug concentration may explain the reduced dosage requirement for thiopentone in patients with renal failure. 2s A study of thiopentone kinetics in renal failure 29 showed Anaesthesia and lntens;ve Care, Vol. 1 J, No. 4, November, 1983 increases in both the volume of distribution and the clearance of thiopentone, both of these changes being related to reduced protein binding. Because these changes were approximately equal, there was no change in the drug elimination half-life. The conclusion was that, assuming that central nervous system sensitivity to thiopentone was unchanged in renal failure, the total dose required for induction of anaesthesia would be unaltered. However, it was suggested that a slower rate of administration was needed in the presence of reduced protein binding to prevent transient excessive thiopentone concentrations in the brain and heart during initial distribution of the drug.
The sensitivity of uraemic patients to the respiratory depressant effects of morphine may be increased because of decreased plasma protein binding. 30 Thus morphine should be administered to uraemic patients by careful titration, particularly those with low serum albumen levels and/or concurrent liver disease.
A knowledge of possible protein binding changes in uraemia is important also in the interpretation of available serum concentrations of a drug. Most laboratories give total drug concentration. In situations where serum albumen is depressed such as nephrotic syndrome, or where the drug binding to plasma protein is decreased by competition with uraemic products, the bound fraction may be markedly diminished.
In these circumstOances a normal total drug concentration may be associated with serious adverse reactions as the free drug concentration is increased.
Metabolism
Changes of drug metabolism in uraemic patients will have significant effects on the elimination of a drug only when metabolism is a major route of elimination. Reidenberg 31 reviewed this subject showing that the major pathways of drug metabolism, oxidation and glucuronide formation, appear normal in uraemia but that some of the minor pathways are slowed. Ester hydrolysis has been studied using procaine as an example. Significant prolongation of procaine TYz in uraemia 32 was shown, the cause being low levels of drug metabolising enzyme. Although hydrolysis is a relatively minor metabolic pathway, its impairment may be of consequence for such drug esters as clindamycin phosphate,33 erythromycin estolate 34 and indanyl carbenicillin 35 which have to be hydrolysed in the body in order to release the active drug form. 7 Some other drugs such as p-aminosalicylic acid,36 sulfisoxazole 37 and some other sulphonamides and hydralazine are metabolised slowly in uraemia.
Drug elimination
Compounds are cleared by the kidneys by passive filtration through the glomerulus and also by active secretion into the kidney tubules. Once in the tubules of the nephron, compounds may be passively reabsorbed back into the circulation. The first two mechanisms contribute positively, the last negatively, to overall renal clearance. The extent to which renal failure influences duration of action is a function of the percentage of circulating drug cleared through the kidney unchanged, and the pharmacological activity of its metabolites. The majority of studies have dealt with antibiotics, relatively few with other drugs. Generally, these studies have described relationships between changes in renal function and associated changes in the elimination characteristics of a particular drug or class of drugs, and have assumed that drug metabolites have little or no pharmacological effect. This assumption may be invalid for some drugs. It has been suggested that the toxic effects due to nitrofurantoin in uraemic patients may be due to increased circulating levels of metabolites 38 and the possible interactions between metabolites at high circulating levels. Another example is that of the slowed elimination in renal failure of norpethidine, a metabolite of pethidine. This metabolite has less analgesic activity, but more convulsive activity than its parent compound and has been reported to cause severe irritability and twitching in renal failure patients dosed with pethidine. 39 Metabolites of clofi bra te, 40 allopurinol, 41 digitoxin, 42 amylobarbitone 43 and methyldopa 44 have caused problems in renal failure also.
Relationship of drug elimination to renal function
The relationship between the elimination half-life of some antibiotics and creatinine clearance (CLCR) was first established by Kunin,45 who described the following basic types of drugs: Type A (drugs eliminated almost entirely by the kidneys) TY2 increases only slowly with decreasing values of CLCR until a critical value of CLCR = 10 to 20 mllminute is reached. Below this point, however, TY2 increases dramatically with further decreasing values of CLCR. Type B (drugs eliminated almost entirely by extrarenal mechanisms) T Y2 remains practically unchanged with decreasing values of CLCR.
Drugs that have both renal and extrarenal elimination routes show an intermediate behaviour and may be called Type C drugs.
It is clear that the influence of renal impairment on drug half-life will be a direct function of the percentage of drug cleared through the kidney. If the half-life of a drug which is cleared essentially unchanged via the kidney is plotted against the endogenous creatinine clearance, the resulting curve will be a hyperbola. On the other hand, the curve obtained from a drug which is extensively metabolised would be relatively flat. Examples of these types of drugs are cefazolin 5 and minocycline 46 and the curves obtained for these two agents are shown in Figure 1. 7 The curve for cefazolin is typical for drugs cleared from the body unchanged. The drug half-life increases slowly until creatinine clearance falls below about 30 mllminute. As creatinine clearance is further reduced the drug half-life is markedly increased. For minocycline there is little variation of TY2 with decreasing values of creatinine clearance since other mechanisms for its elimination exist. Kunin 45 recognised that ". . . exact dosage schedules are difficult to formulate in these patients because of the nature of the curve relating half-life to renal function". Dettli 1 , 47, 48 proposed that the only way to overcome this difficulty was by analysing the relationship between drug elimination rate and creatinine clearance in such a way that the curve could be described mathematically. In this model, the simplest description of the time course of circulating drug concentrations assumes that the drug rapidly equilibrates into the body fluids and tissues which comprise its volume of distribution. The overall elimination rate constant (K) is the sum of the renal (Kr) and non-renal (Km) elimination rate constants (Equation 2). K=Km+Kr ... (2) Since the kidney behaves functionally in renal impairment as though there is a numerical reduction in the numbers of neprhons, the renal elimination of most antibiotic agents is proportional to the creatinine clearance (Equation Dosage adjustment may be required in patients with renal failure to avoid accumulation of drug to toxic concentrations during repeated dosing. This is unlikely to occur with a single dose of drug, but prolonged duration of action of the drug will occur associated with decreased elimination. It is with intermittent administration and drug infusion regimens that the most danger of drug accumulation and toxicity exists. In chronic drug treatment a maintenance dose, (d), usually is administered repeatedly at a fixed dosage interval (t). The amount of drug eliminated during the first dosage interval is a constant fraction of the amount of drug in the body after the first dose, assuming first order kinetics. It follows that the drug retained in the body at the end of the dosage interval also must be a constant fraction of the amount of drug after the first dose. This amount of drug persisting is the basis for drug accumulation since the second dose will superimpose itself on this drug level. However, as drug levels in the body increase so will the amount of drug eliminated per dosage interval to a point where the amount eliminated per dosage interval is equal to the administered dose. At this point the accumulation limit or steady state will have been reached.
Whether or not dose adjustment is necessary depends on the degree of renal impairment, the percentage of drug cleared unchanged by the kidney, and the therapeutic index of the particular drug. Most penicillins and some cephalosporins have wide therapeutic indices, and dose adjustments for these agents may not be necessary, even in moderate renal impairment. Other drugs like the aminoglycosides have narrow therapeutic indices and dosages of these must be controlled accurately to avoid toxic effects. Welling and Craig 7 have summarised the numerous formulae, tables, nomographs and computer programs that have been described over the last decade to facilitate dosage adjustment in renal failure. Most of them have assumed an absence of metabolite activity, unchanged distribution volume, and plasma protein binding in uraemia, and that all extrarenal elimination routes are unaffected by the uraemic condition. The objective of most methods has been to provide the same maximum or mean steady state serum concentrations of drugs in the uraemic patient, as are observed in patients with normal renal function. However, high correlations have been found between gentamycin toxicity and minimum circulating drug concentration,7,49,5o rather than maximum or mean values, which suggests that this objective may not be appropriate for certain drug regimens.
A more general summary of dosage modification in renal failure may be found in the review of Bennett. 51 As stated previously, in order to determine whether or not dosage adjustment is necessary one must make an assessment· of the patient's renal function. Glomerular filtration rate (GFR) is the important variable relating to integrity of renal drug elimination mechanisms. There is not a linear relationship between GFR and blood urea nitrogen (BUN) or serum creatinine. BUN is an unsuitable indicator of renal function on which to base drug dosage since it may be influenced by extrarenal factors such as diet, catabolic state and steroid therapy. Therefore it is necessary to know the relationship between serum creatinine and creatinine clearance to be able to make inferences about GFR. For example, if a serum creatinine result of 1 mg/ dl is equated to a creatinine clearance of 100 mllmin in a particular patient, a doubling of the serum value to 2 mg/ dl will correspond to a halving of creatinine clearance to 50 mllmin. Because of individual differences in creatinine production related to lean body weight, the above relationship must be known for each patient. To avoid the need for urine collection, the following formula for creatinine clearance has been proposed 5 1, 52 (Equation 6 ).
(140 -age) x (body weight in kg)
CLCR=
.~) 72 x serum creatinine concentration Having established this relationship one must decide whether or not dosage adjustment is necessary. The risk of significant retention relates to those drugs which primarily depend on the kidney for elimination and this, therefore, emphasises the need for adequate pharmacokinetic knowledge. 
Loading dose in renal failure
Even with drugs which will require modification of subsequent doses it is considered most practical to administer the usual loading dose to patients with renal failure. 53 ,54 The reason for this is that if usual maintenance doses are administered at greater than normal dosing intervals, in consideration of the prolonged elimination half-life, then considerable delay would occur before therapeutic levels of the drug would be reached. This is because, to reach approximately 90070 of the desired ultimate mean steady state concentration, a period of 3.3 times the elimination half-life is required, if only maintenance doses are used. In seriously ill patients, severe infection being relatively common in renal failure patients, such a delay in achieving effective therapy may be dangerous. In clinical situations where a reduced volume of distribution of the drug is suspected, such as in extracellular fluid volume depletion, it would be wise to reduce the loading dose of potentially toxic drugs. 51 This applies particularly to the cardiac glycosides, and the aminoglycoside antibiotics.
With respect to subsequent maintenance doses the desired drug level can be obtained by one of the following two methods or some compromise between them.
Dosage interval extension
Dosage interval extension, keeping the size of dose constant, is commonly used particularly with drugs having a long serum half-life. 54 A theoretical objection to this method is that with short half-life drugs like the common aminoglycoside antibiotics, gentamycin, tobramycin and amikacin, prolonged periods below the therapeutic range might result from the resultant peak and trough effect. This, however, has not been borne out in studies, and also it has been shown that frequent smaller doses of aminoglycosides may have greater nephrotoxicity in experimental animals. 55 ,56 
Dosage reduction
By keeping the usual dosage intervals but reducing the dosage size in proportion to the degree of renal failure, the difference between peak and trough levels is minimised. Problems with this method are that if the dose is too high or the degree of renal function is overestimated, serious toxIcity can result. As previously discussed with the aminoglycosides as an example, nephrotoxicity may be enhanced by the relatively constant blood concentrations keeping saturated the receptors for drug transport into proximal tubular cells. 51 ,56 For practical purposes a combination of the above two methods is used. By utilising these principles combined with measurement of serum drug concentrations (where available) most clinical problems of impaired renal drug elimination can be managed satisfactorily. Usual therapeutic ranges are being increasingly defined for many groups of drugs used to treat patients with renal failure including anticonvulsants, cardiac glycosides, antiarrythmics and psychotherapeutic agents. In addition to knowledge of the drug concentrations, alterations of the physiological and biochemical conditions which might affect drug action must also be considered. For example, digitalis intoxication can occur with serum concentrations well within the therapeutic range if significant hypokalaemia 2 give examples of drugs commonly used in anaesthesia and intensive care practice where dosage modification may be necessary in patients with renal failure.
Dialysis and dosage modification
Both haemodialysis and peritoneal dialysis are able to remove drugs from the circulation.
The degree to which a drug is removed during dialysis depends on the particular dialysis technique as well as certain properties of the drug, including molecular weight, water solubility, protein binding, inherent plasma clearance and dialysis clearance. A useful review of the many variables which affect drug removal during dialysis has been published by Gibson and Nelson.71 Less significant losses are usually observed with peritoneal dialysis than with haemodialysis. For drugs which are significantly cleared by haemodialysis it is common practice to omit a dose just preceding dialysis and during dialysis and to replace a full maintenance dose after dialysis. 57 . 72 Table 3 lists common drugs requiring such supplementary dosage.
Electrolyte changes during dialysis may affect drug activity:'Rapid shifts of potassium, calcium and magnesium may produce digitalis intoxication. Conversely, dialysis is able to correct metabolic abnormalities caused by drugs, such as large sodium loads with carbenicillin, metabolic acidosis with phenformin, hyperkalaemia with penicillin and potassium and hypermagnesaemia with antacids. 51
